Amylyx Pharma ends Q2 2026 with $250.8M cash, runway into 2028 ahead of Avexitide Phase 3 readout

Amylyx Pharma (NASDAQ: AMLX) reported Q2 2026 cash and marketable securities of $250.8 million, down from $279.8 million in Q1 2026, with a cash runway into 2028. The company said it is preparing for pivotal Phase 3 LUCIDITY top-line data for Avexitide, targeting an NDA submission and potential commercialization in 2027.

Detected & updated continuously · Source: Nebula